The U.S. Food and Drug Administration has granted its approval for the winder use of the GlaxoSmithKline asthma drug known as Flovent HFA.

Flovent can now be prescribed for children ages 4 to 11, GSK said Thursday.

Some 3.6 million children ages 5-11 have asthma, according to federal health statistics cited by GSK.

Flovent was approved for use for patients ages 12 and older in 2004.